- Home
- ASTL vs CRGX Comparison
ASTL vs CRGX Comparison
Compare ASTL & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTL
- CRGX
- Stock Information
- Founded
- ASTL 1902
- CRGX 2021
- Country
- ASTL Canada
- CRGX United States
- Employees
- ASTL N/A
- CRGX N/A
- Industry
- ASTL Steel/Iron Ore
- CRGX
- Sector
- ASTL Industrials
- CRGX
- Exchange
- ASTL Nasdaq
- CRGX Nasdaq
- Market Cap
- ASTL 532.0M
- CRGX 190.0M
- IPO Year
- ASTL N/A
- CRGX 2023
- Fundamental
- Price
- ASTL $7.09
- CRGX $4.46
- Analyst Decision
- ASTL
- CRGX Hold
- Analyst Count
- ASTL 0
- CRGX 7
- Target Price
- ASTL N/A
- CRGX $4.67
- AVG Volume (30 Days)
- ASTL 1.3M
- CRGX 502.9K
- Earning Date
- ASTL 07-15-2025
- CRGX 08-11-2025
- Dividend Yield
- ASTL 2.81%
- CRGX N/A
- EPS Growth
- ASTL N/A
- CRGX N/A
- EPS
- ASTL N/A
- CRGX N/A
- Revenue
- ASTL $1,635,857,227.00
- CRGX N/A
- Revenue This Year
- ASTL $0.95
- CRGX $57.81
- Revenue Next Year
- ASTL $21.63
- CRGX N/A
- P/E Ratio
- ASTL N/A
- CRGX N/A
- Revenue Growth
- ASTL N/A
- CRGX N/A
- 52 Week Low
- ASTL $4.17
- CRGX $3.00
- 52 Week High
- ASTL $12.14
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- ASTL 66.88
- CRGX 57.89
- Support Level
- ASTL $6.39
- CRGX $4.09
- Resistance Level
- ASTL $7.25
- CRGX $4.51
- Average True Range (ATR)
- ASTL 0.35
- CRGX 0.18
- MACD
- ASTL 0.03
- CRGX 0.00
- Stochastic Oscillator
- ASTL 87.80
- CRGX 77.18
About ASTL Algoma Steel Group Inc.
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.